Dogwood Therapeutics Inc.

7.50
-1.27 (-14.48%)
At close: Feb 11, 2025, 3:59 PM
7.65
2.00%
After-hours Feb 11, 2025, 06:00 PM EST
undefined%
Bid 7.35
Market Cap 9.99M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -5.16
PE Ratio (ttm) -1.45
Forward PE n/a
Analyst n/a
Ask 7.65
Volume 501,953
Avg. Volume (20D) 2,654,031
Open 9.09
Previous Close 8.77
Day's Range 6.81 - 9.70
52-Week Range 1.62 - 29.28
Beta undefined

About DWTX

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, att...

Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 4
Stock Exchange NASDAQ
Ticker Symbol DWTX
3 weeks ago
+68.45%
Dogwood Therapeutics shares are trading higher aft... Unlock content with Pro Subscription
2 months ago
-37.71%
Dogwood Therapeutics shares are trading lower. The company announced top line data from the recently completed BHC IMC-2 Long-COVID study.
No News article available yet